1. Academic Validation
  2. Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats

Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats

  • Animal Model Exp Med. 2021 Mar 23;4(3):243-248. doi: 10.1002/ame2.12162.
Pranav Nayak B 1 Nathani Minaz 1 Khadar Pasha 1
Affiliations

Affiliation

  • 1 Pharmacology Department and Al-Ameen College of Pharmacy and Rajiv Gandhi University Bangalore India.
Abstract

Diabetic neuropathy is a disorder that affects various regions of the nervous system and there is no specific treatment available for it. This study evaluated the protective effect of molsidomine in diabetic neuropathy in rats. Diabetes was induced in male Wistar rats by administrating streptozotocin (52 mg/kg IP). Diabetic rats were treated with molsidomine 5 mg/kg po and 10 mg/kg po. After 8 weeks of treatment, motor coordination, mechanical allodynia, mechanical hyperalgesia, nerve conduction velocity, and glycosylated Hemoglobin were assessed. Thereafter, Animals were killed and the sciatic nerve was isolated for measurement of reduced glutathione and lipid peroxidation, and histopathological analysis. Treatment with molsidomine significantly improved motor coordination, paw withdrawal threshold, mechanical threshold, and nerve conduction velocity. Furthermore, molsidomine treatment also reduced malondialdehyde levels and prevented depletion of reduced glutathione in the sciatic nerve homogenate. Histopathology revealed that molsidomine treatment maintained normal architecture of the sciatic nerve. The results of our study strengthen the alternative use of molsidomine in diabetic neuropathy.

Keywords

Wistar rats; diabetic neuropathy; molsidomine; streptozotocin.

Figures
Products